No trial has yet shown whether micro-dosing Mounjaro works. As of 14 October 2026, the literature is letters, commentaries, a brief report, a narrative review and one records study, and the first randomised trials have not reported. Tirzepatide's elimination half-life is about 5 to 6 days (half-life), and at GetLean, Dr Quek decides each dose change at the monthly review.
Micro-dosing here means using less than the registered schedule, or leaving longer gaps between injections, and the first randomised trials of it are registered. The labels also set steady state, reached after four weeks of once-weekly dosing, and a minimum gap if the injection day moves (steady state, product information). The FDA's warning concerns compounded product used beyond the approved label, not below it (FDA 2026). A dose and an interval are clinical decisions made about a specific person.
In Singapore, tirzepatide is registered as Mounjaro, and semaglutide injection as Wegovy for weight management and as Ozempic for type 2 diabetes. The figures in this article are given by molecule, as the trials and product labels report them.
Micro-dosing (GLP-1): an informal term for deliberately using less medicine than the registered dosing schedule specifies — a smaller amount, a longer gap between injections, or both. It is not a clinical term, and no medicines regulator recognises it.
At GetLean, microdosing means taking the medicine below its labelled dose or schedule, set with Dr Quek as part of the GetLean GLP-1 Taper Plan: GLP-1 microdosing at GetLean, step by step.
What does the evidence on micro-dosing consist of?
Letters and commentaries, one records study, and no trial yet.
A PubMed search on 14 October 2026 for micro-dosing crossed with GLP-1, semaglutide and tirzepatide returns 13 records. Eight are about the practice: a letter and a short article on dialling sub-label amounts from multi-dose pens, a comment on the first letter, a later letter, a brief report, a narrative review, a commentary that calls high-quality evidence "essentially absent" (Beck 2026), and one records study. The other five use the word in other senses or are unrelated. The letters, the comment and the short article are indexed with no abstract and carry no data. The brief report comments on the practice rather than testing it — it calls the practice "subtherapeutic microdosing", names its drivers as affordability, "gastrointestinal tolerability and 'vanity weight'", and sets out to address "the safety risks associated with pen manipulation, compounded vials, and medication sharing; and the legal pitfalls surrounding compounded 'copies.'" (Trainer 2026). Only the records study reports original data, and its authors say it does not establish intentional micro-dosing (Murugadoss 2026).
The picture outside the journals is the same. A search for a position statement from an obesity professional body found none. A search of HSA's published material on GLP-1 medication found its suicidality safety review and its alerts on adulterated slimming products, and nothing on compounding, altered dosing or micro-dosing, so no Singapore regulator position on the practice should be inferred from it.
One thing that absence does not mean: it does not mean the practice has been shown not to work. No trial has reported on it. Those are different statements, and both errors are equally common.
Coming off GLP-1 with the GetLean GLP-1 Taper Plan: microdosing, step by step
When you have reached your goal weight and want to come off your GLP-1 medicine, stopping all at once is usually the hardest way to do it. Hunger and cravings come back in a rush, eating goes up, and the weight tends to follow.
The GetLean GLP-1 Taper Plan brings your appetite back gradually instead. Each step lets a little hunger return, so you can get used to your own hunger cues again and rely on the habits you built with us before you take the next step down.
What we mean by microdosing
There is no single agreed definition of microdosing. At GetLean, microdosing means taking the medicine below its labelled dose or schedule. The GetLean GLP-1 Taper Plan gets you there in two ways, and often uses both.
1. Lower doses
GLP-1 medicines are started at a low dose and stepped up to an effective one. Tapering runs the same steps in reverse. You come down to the dose you were on before and stay there until your hunger and cravings are at a level you can handle. Only then do we step down again.
It is normal to stay at an in-between dose for a while. For example, someone who reached their goal on Mounjaro 15 mg might come down to 10 mg, find it hard to keep to their diet, and stay on 10 mg until they are ready. We only take the next step when you feel ready and confident you can manage the hunger and cravings that come back.
2. Longer gaps between injections
Instead of one injection every 7 days, you might inject every 8, 9 or 10 days. In those extra days your appetite gradually returns, and you get a real sense of how well you can manage it before your next dose.
Once you are on the lowest dose (Mounjaro 2.5 mg), injections can move to once every two weeks. From there, when you feel in control and no longer need the medicine to curb your appetite and cravings, you can stop completely.
Using both together
The two can be combined: for example, going from Mounjaro 15 mg once a week to 10 mg every 10 days.
One safety rule
On higher doses (7.5, 10 or 15 mg), if you go more than 10 days without an injection, the taper restarts on a lower dose. Taking a high dose after a long break can cause stomach and gut side effects, including pancreatitis. Speak to us before your next dose.
Your plan is your own
Every GetLean GLP-1 Taper Plan is set with Dr Quek, around your habits, your lifestyle and how confident you feel at each step. Book a consultation to plan yours.
Why do people do it?
Cost, mostly, and tolerability.
One peer-reviewed characterisation names affordability first, describing "ongoing affordability barriers [that] continue to drive patient desperation, fueling a shift toward unsupervised strategies such as 'microdosing' and the purchase of illicit 'research-grade' peptides from online sources and unregulated providers including medical spas" (Trainer 2026).
The motivation is real and deserves a straight answer rather than a lecture. These medicines are expensive, a course runs for months or years, and someone doing arithmetic on a pen that could be made to last longer is responding to something genuine. The motivation and the method are separate questions, though, and only the first has an obvious answer. Where cost pushes people towards unregulated supply instead, the risks change shape entirely — compounded semaglutide and Telegram sellers covers those.
What do the labels actually say?
This is the firm ground, and it is worth being precise about what it does and does not cover.
Half-life. Semaglutide's elimination half-life is about one week; the US label states it will be present in the circulation for about 5 to 7 weeks after a last 2.4 mg dose, while the EU label says approximately 7 weeks after the same dose (half-life, steady state). Tirzepatide's is approximately 5 to 6 days in the US label and approximately 5 days in the EU (half-life, steady state). A half-life describes drug concentration, not how long an effect lasts, so it cannot tell anyone how long appetite suppression persists.
Time to steady state. Tirzepatide's label states, identically in the US and EU versions, that steady-state plasma concentrations are achieved after four weeks of once-weekly administration. Semaglutide's labels state no time to steady state at all — a full-document search of both finds steady-state concentrations and never a time, only that exposure "was stable with time as assessed up to week 72" (steady state). A figure computed from the half-life is not label information and should not be presented as if it were.
The dosing interval has a floor, not a ceiling. Both labels permit moving the injection day: the day of weekly administration can be changed if necessary, provided a minimum gap is observed — and the same passage requires once-weekly dosing to continue afterwards. No sentence anywhere in either label sanctions a longer interval. The only upper bound that exists is the missed-dose rule, and it treats a longer gap as a dose to be skipped, not a schedule to adopt (product information).
And the Singapore rule is not the US rule. Singapore counts time since the missed dose; the US semaglutide instruction works on a different calculation — proximity to the next scheduled dose (Singapore NDF) — so advice found online usually describes a rule that does not apply here. Missed a GLP-1 dose sets out the Singapore instruction in full.
Put together, a stretched interval is not a slower schedule in label terms. Past the threshold it is a missed dose, and the label's instruction is to skip it. One note on the tirzepatide figures: in Singapore tirzepatide's current registrations carry both a type 2 diabetes and a weight-management indication, while the 2023 injection registration SIN16718P carries type 2 diabetes only (Singapore NDF). Its dosing rules appear here as label facts, not as a recommendation.
That is the label. Under the GetLean GLP-1 Taper Plan, set with Dr Quek, microdosing means taking the medicine below its labelled dose or schedule: instead of one injection every 7 days, you might inject every 8, 9 or 10 days, and once you are on the lowest dose (Mounjaro 2.5 mg), injections can move to once every two weeks (GLP-1 microdosing at GetLean, step by step). On higher doses (7.5, 10 or 15 mg), if you go more than 10 days without an injection, the taper restarts on a lower dose. Taking a high dose after a long break can cause stomach and gut side effects, including pancreatitis. Speak to us before your next dose.
The FDA warning people cite points the other way
This is the single easiest error on the topic, and it is worth correcting directly.
The FDA statement on compounded GLP-1 products is regularly quoted as though the agency had warned about micro-dosing. It has not. Every altered-dosing concern on that page runs in the opposite direction: the agency describes adverse-event reports in patients prescribed compounded semaglutide or tirzepatide "in doses beyond what is in the FDA-approved drug label", defined as "using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule)". As of 31 May 2026 it had received 990 such reports for compounded semaglutide and more than 730 for compounded tirzepatide, and it states these are likely under-reported (FDA 2026).
A separate FDA alert is relevant, though not in the way people expect. In July 2024 the agency reported patients administering five to 20 times the intended dose of compounded semaglutide, some requiring hospitalisation, after confusing millilitres, milligrams and syringe units while drawing a dose from a vial (FDA MedWatch 2024). The hazard there is measurement error by a person drawing their own dose — the exact step that dose-splitting and pen manipulation reintroduce. Both documents are US statements about compounded, non-approved product, and neither describes Singapore or the licensed pre-filled pens.
What is known about low maintenance doses?
Something, and it is not a test of micro-dosing.
In a cohort of 7,881 US adults with overweight or obesity and without type 2 diabetes, 80.8% were on a low maintenance dose (below semaglutide 1.7 mg or tirzepatide 10 mg), and mean weight reduction at one year across the whole group, including people who stopped, was 8.7% — well below the phase-3 trial figures. Among those who stayed on treatment at a high maintenance dose, one-year reduction was 13.7% for semaglutide and 18.0% for tirzepatide (Gasoyan 2025).
Two things have to be read with it. It is observational, so people on lower doses may be there because of side effects, cost, access or a clinician's judgement, and it cannot show that a lower dose causes less weight loss. And its "low" category means ordinary titration doses rather than the sub-therapeutic fractions people mean by micro-dosing. It is nevertheless the nearest real-world data touching the question, and the direction it points is not the direction the practice's advocates claim. Individual results vary, and these figures describe the population studied.
There is also a claim in circulation on commercial telehealth pages that spacing injections further apart preserves most of the weight loss. It has no primary source behind it — no trial, no cohort, no pharmacokinetic study.
Why the dose belongs to a prescriber
Because a dose is a judgement about a particular person, and a schedule written for everyone is a judgement about nobody.
A prescriber can see how someone has responded so far, what side effects they have had, what else they take, what the goal is, and whether a smaller dose would be the lowest effective dose for them or simply less medicine. The principle is the lowest effective dose — the smallest dose that still achieves the clinical goal, rather than the highest dose a person can tolerate. It differs between people, which is why it cannot be reduced to a number.
A supervised route to a lower dose already exists inside the labels, and it is not symmetrical between the two drugs. Singapore's semaglutide product information carries an explicit tolerability provision, word for word with the EU: consider delaying dose escalation or lowering to the previous dose until symptoms have improved (Singapore NDF). Singapore's tirzepatide product information contains no such sentence anywhere in its dosing section, matching the EU (Singapore NDF). So "go slower if it is rough" is confirmed for semaglutide only, and even there it is written as an instruction to the prescriber. How GLP-1 dose titration works sets out both schedules. Can you stay on the lowest dose of Mounjaro (tirzepatide), 2.5 mg? sets out what the labels and the studies show.
The safety point stands separately and does not depend on the efficacy one. Dialling a sub-label amount from a pen, splitting doses, or drawing from a vial reintroduces the measurement step that pre-filled pens exist to remove — the specific mechanism behind the dosing-error reports above.
Why the missing evidence matters more here than elsewhere
In most of this field the gap is between good evidence and better evidence. Trials exist; they are too short, or in the wrong population, and the argument is about how far to stretch them. Here there is almost nothing to stretch. No published trial. No pharmacokinetic study. No regulator statement. No professional-body position. One records study, whose authors say it does not establish intentional micro-dosing.
That matters because the thing this practice changes — how much drug is in someone's system, and for how long — is precisely what pharmacokinetic studies exist to measure. Every registered figure in this article comes from a study designed to answer a dosing question. Nothing equivalent exists for a schedule someone has assembled themselves.
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. That points towards the lowest effective dose and towards a planned exit, both under supervision. It does not point towards a schedule improvised around a pen. The duration question runs into a similar gap, and we cover it in how long should you stay on GLP-1.
Individual results vary, and clinical-trial figures describe the populations studied. Never change the amount or the timing of a prescribed medication on your own; that is a conversation with the doctor who prescribed it.
Common questions
What is micro-dosing GLP-1 medication?
An informal term for deliberately using less medicine than the registered dosing schedule specifies — a smaller amount, a longer gap between injections, or both. It is not a clinical term, no medicines regulator recognises it, and one peer-reviewed description of it calls it subtherapeutic and unsupervised (Trainer 2026).
Is there any evidence that micro-dosing GLP-1 medication works?
Not from a trial yet. A PubMed search on 14 October 2026 for micro-dosing crossed with GLP-1, semaglutide and tirzepatide returns 13 records, eight of them about the practice: letters, commentaries, a brief report, a narrative review and one records study (Trainer 2026; Beck 2026). None is a trial. The records study followed people who stayed on the lowest starting dose for six months or more, and its authors say that pattern may overlap with, but does not establish, intentional micro-dosing (Murugadoss 2026). Two randomised trials of semaglutide micro-dosing are registered, and neither has reported results (NCT07325500; NCT07092605). That means it is untested, not that it has been shown not to work.
Has the FDA warned about micro-dosing GLP-1 medication?
No, and this is the most common misreading. The FDA's compounded-GLP-1 statement warns about doses beyond the approved label — its words are using more product in a single dose, taking doses more frequently, or increasing the amount more quickly (FDA 2026). Its concern runs in the opposite direction, and it addresses compounded product rather than licensed pens.
Can you take a GLP-1 injection less often than once a week?
The labels set a minimum interval, never a maximum. The injection day can be moved provided a minimum gap is observed, with once-weekly dosing continuing afterwards; a longer gap is defined as a missed dose to be skipped (product information). Any change to timing is a decision for the prescribing doctor. That is the label. Under the GetLean GLP-1 Taper Plan, set with Dr Quek, instead of one injection every 7 days, you might inject every 8, 9 or 10 days, and once you are on the lowest dose (Mounjaro 2.5 mg), injections can move to once every two weeks (GLP-1 microdosing at GetLean, step by step). On higher doses (7.5, 10 or 15 mg), if you go more than 10 days without an injection, the taper restarts on a lower dose. Taking a high dose after a long break can cause stomach and gut side effects, including pancreatitis. Speak to us before your next dose.
Does a lower dose still produce weight loss?
In routine US practice, 80.8% of patients were on a low maintenance dose (below semaglutide 1.7 mg or tirzepatide 10 mg), and the whole group, including people who stopped, averaged 8.7% weight loss at one year, against 13.7% for semaglutide and 18.0% for tirzepatide among those who stayed on treatment at a high maintenance dose (Gasoyan 2025). That is observational and cannot separate the dose from the reason for it, and its lower doses are ordinary titration doses rather than the fractions meant by micro-dosing. Individual results vary.
How does GetLean use microdosing to come off GLP-1?
At GetLean, microdosing means taking the medicine below its labelled dose or schedule, as part of the GetLean GLP-1 Taper Plan. The GetLean GLP-1 Taper Plan gets you there in two ways, and often uses both: lower doses, where you come down to the dose you were on before and stay there until your hunger and cravings are at a level you can handle; and longer gaps between injections, where instead of one injection every 7 days, you might inject every 8, 9 or 10 days. Once you are on the lowest dose (Mounjaro 2.5 mg), injections can move to once every two weeks. On higher doses (7.5, 10 or 15 mg), if you go more than 10 days without an injection, the taper restarts on a lower dose. Taking a high dose after a long break can cause stomach and gut side effects, including pancreatitis. Speak to us before your next dose.